Journal
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Volume 735, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.abb.2023.109510
Keywords
Lysosomal storage diseases; Niemann-Pick type C; Miglustat; Neurodegeneration; Next generation sequencing
Categories
Ask authors/readers for more resources
Niemann-Pick type C1 (NPC1) is a fatal inherited disease caused by pathogenic variants in the NPC1 gene. The study aimed to assess peripheral neurodegeneration biomarkers in NPC1 patients and found that those treated with miglustat showed decreased levels of PAI-1 and PDGF-AA, and normalized levels of 3ll,5a,6ll-triol. This is the first study to analyze these markers in NPC1 patients' plasma.
Niemann-Pick type C1 (NPC1) is a fatal inherited disease, caused by pathogenic variants in NPC1 gene, which leads to intracellular accumulation of non-esterified cholesterol and glycosphingolipids. This accumulation leads to a wide range of clinical manifestations, including neurological and cognitive impairment as well as psychiatric disorders. The pathophysiology of cerebral damage involves loss of Purkinje cells, synaptic disturbance, and demyelination. Miglustat, a reversible inhibitor of glucosylceramide synthase, is an approved treatment for NPC1 and can slow neurological damage. The aim of this study was to assess the levels of peripheric neurodegeneration biomarkers of NPC1 patients, namely brain-derived neurotrophic factor (BDNF), platelet-derived growth factors (PDGF-AA and PDGF-AB/BB), neural cell adhesion molecule (NCAM), PAI-1 Total and Cathepsin-D, as well as the levels of cholestane-3ll,5a,6ll-triol (3ll,5a,6ll-triol), a biomarker for NPC1. Molecular analysis of the NPC1 pa-tients under study was performed by next generation sequencing (NGS) in cultured fibroblasts. We observed that NPC1 patients treated with miglustat have a significant decrease in PAI-1 total and PDGF-AA concentrations, and no alteration in BDNF, NCAM, PDGF-AB/BB and Cathepsin D. We also found that NPC1 patients treated with miglustat have normalized levels of 3ll,5a,6ll-triol. The molecular analysis showed four described mutations, and for two patients was not possible to identify the second mutated allele. Our results indicate that the decrease of PAI-1 and PDGF-AA in NPC1 patients could be involved in the pathophysiology of this disease. This is the first work to analyze those plasmatic markers of neurodegenerative processes in NPC1 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available